(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
12 August 2021 (12.08.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/156326 A1

(51) International Patent Classification:
A61K 39/395 (2006.01) *C07K 16/28* (2006.01)
A61P 35/00 (2006.01) *C07K 16/46* (2006.01)

(21) International Application Number:
PCT/EP2021/052587

(22) International Filing Date:
04 February 2021 (04.02.2021)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

62/970,046	04 February 2020 (04.02.2020)	US
63/027,702	20 May 2020 (20.05.2020)	US
63/110,633	06 November 2020 (06.11.2020)	US

(71) Applicants: **GENMAB A/S** [DK/DK]; Kalvebod Brygge 43, 1560 Copenhagen V (DK). **BIONTECH SE** [DE/DE]; An der Goldgrube 12, 55131 Mainz (DE).

(72) Inventors: **SAHIN, Ugur**; c/o BioNTech SE, An der Goldgrube 12, 55116 Mainz (DE). **MUIK, Alexander**; c/o BioNTech, SE An der Goldgrube 12, 55131 Mainz (DE). **ALTINTAS, Isil**; c/o Genmab B.V., Uppsalalaan 15, 3584 CT Utrecht (NL). **FORSSMANN, Ulf**; c/o Genmab A/S, Kalvebod Brygge 43, 1560 Copenhagen V (DK). **SASSER, Kate**; c/o Genmab US, Inc., 777 Scudders Mill Rd., Plainsboro, New Jersey 08536 (US). **JURE-KUNKEL, Maria, N.**; c/o Genmab US, Inc., 777 Scudders Mill Rd., Plainsboro, New Jersey 08536 (US). **GUPTA, Manish**; c/o Genmab US, Inc., 777 Scudders Mill Rd., Plainsboro, New Jersey 08536 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*

WO 2021/156326 A1

(54) Title: ANTIBODIES FOR USE IN THERAPY

(57) Abstract: The present invention relates to a method for reducing or preventing progression of a tumor or treating cancer. The method comprises administering to a subject, a binding agent comprising a first binding region binding to human CD137 and a second binding region binding to human PD-L1. The amount of binding agent administered in each treatment cycle is preferably about 0.3-5 mg/kg body weight or about 25-400 mg in total.